A Study of T-DXd in Patients with Selected HER2-overexpressing Tumors

Trial Identifier: D781AC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo Co., Ltd.
NCTID:: NCT06271837
Start Date: February 2024
Primary Completion Date: October 2025
Study Completion Date: April 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100142
CN Changchun, CN, 130021
CN Changsha, CN, 410013
CN Changzhou, CN, 213004
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Dongyang, CN, 322100
CN Guangzhou, CN, 510145
CN Guangzhou, CN, 510630
CN Haikou, CN, 570311
CN Hangzhou, CN, 310022
CN Harbin, CN, 150081
CN Hefei, CN, 230031
CN Kunming, CN, 650118
CN Lishui, CN, 323000
CN nanchang, CN, 330029
CN shanghai, CN, 200011
CN Shanghai, CN, 200032
CN Shenyang, CN, 110016
CN Xuzhou, CN, 221009
CN Yinchuan, CN, 750004
CN Zhengzhou, CN, 450008